Amgen Inc.

Amgen Fremont Inc.

Dendreon Corporation

Kathy Manchulenko

Ian Nevin Foltz

Jaspal Singh Kang

Orit Foord

Scott L Klakamp

Palaniswami Rathanaswami

Giorgio Senaldi

Raffaella Faggioni

Larry L Green

Li Erran Li

Mary Haak-Frendscho

Gunasekaran Kannan

Ai Ching Lim

John Stephen Babcook

Meina Liang

Xiao Feng

Neeraj Jagdish Agrawal

Qiaojuan Jane Su

Marc A Gavin

Dong Xia

Laura Sekirov

Yen-Wah Lee

Kiran Ahluwalia

Craig Pigott

Cyr Clovis Chua De Imus

Kelly Ann Berry

Christy Ann Thomson

Dina N Alcorn

Eric Alan Butz

Chadwick Terence King

Randal Robert Ketchem

Bruce Alan Keyt

Edwin L Madison

Xiaoshan Min

Francine Zhifen Chen

Yannick Bulliard

Marissa Mock

Jennifer Hope Richardson

Agnieszka Kielczewska

Sue J Sohn

Li Li

Stanislaw K Morkowski

Wayne R Godfrey

Caroline Darne Scatena

Peter Koon Bong Ling

Randal Robert Ketchum

Rozanne Lee

Scott Klakamp

Meina L Liang

Jennifer H Richardson

Peter Koon Ling

Marc Alain Gavin

Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

Interleukin-2 muteins for the expansion of T-regulatory cells

Provided herein are TIGIT binding proteins, CD112R binding proteins, and combinations thereof. Also provided are compositions comprising TIGIT binding proteins and CD112R binding proteins, optionally further comprising PD-1 binding proteins. Related conjugates, fusion proteins, nucleic acids, vectors, host cells and kits are additionally provided. Further provided are pharmaceutical compositions comprising a TIGIT binding protein, CD112R binding protein, or a combination thereof, optionally, further comprising a PD-1 antigen binding protein, or a conjugate, fusion protein, nucleic acid, vector, or host cell, and a pharmaceutically acceptable carrier, diluent, or excipient, and methods of treating subjects in need thereof.

TIGIT and CD112R blockade

Antibodies directed to the antigen TNF&#x3b1; and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNF&#x3b1;. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

Antibodies directed to tumor necrosis factor and uses thereof

The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided. Additionally, IL-13 dependent biomarkers and methods of their identification and use are also provided.

Fully human monoclonal antibodies to IL-13

Binding proteins, such as fully human monoclonal antibodies and fragments thereof, directed to the antigen Matriptase and uses of such binding proteins are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising heavy and light chain immunoglobulin molecules capable of binding to Matriptase are also disclosed. The invention also discloses cell lines expressing such immunoglobulin molecules and monoclonal antibodies to Matriptase. The antibodies can be used to detect, prevent, and treat diseases such as cancer.

Binding proteins specific for human matriptase

Antibodies directed to tumor necrosis factor

Growing community of inventors

Coquitlam, Canada

Kathy Manchulenko